Adaptive Biotechnologies Corp [ADPT] stock is trading at $16.92, down -2.42%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADPT shares have gain 0.12% over the last week, with a monthly amount glided 16.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on September 30, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Craig Hallum started tracking the stock with Buy rating on June 18, 2025, and set its price target to $15. On March 21, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $15 as its price target on January 05, 2023. Piper Sandler upgraded its rating to Overweight for this stock on December 21, 2022, and upped its price target to $14. In a note dated August 25, 2022, Credit Suisse initiated an Underperform rating and provided a target price of $8 on this stock.
Adaptive Biotechnologies Corp [ADPT] stock has fluctuated between $4.27 and $17.89 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $16.92 at the most recent close of the market. An investor can expect a potential return of 18.2% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Adaptive Biotechnologies Corp [NASDAQ:ADPT] reported sales of 205.22M for the trailing twelve months, which represents a growth of 36.33%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.61 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.45 points at the first support level, and at 15.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.45, and for the 2nd resistance point, it is at 17.98.
Ratios To Look Out For
For context, Adaptive Biotechnologies Corp’s Current Ratio is 2.84. Further, the Quick Ratio stands at 2.75, while the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 12.55, the price to book ratio is 14.33.
Transactions by insiders
Recent insider trading involved PISKEL KYLE, Chief Financial Officer, that happened on May 16 ’25 when 1929.0 shares were sold. Chief Scientific Officer, ROBINS HARLAN S completed a deal on May 01 ’25 to sell 68412.0 shares. Meanwhile, Officer Harlan Robins bought 68412.0 shares on May 01 ’25.
